Phase 2 N=270 Evaluation of Treatments for Homeless Youths
Substance Abuse
Primary: Substance Use — 45.67; 53.60; 49.38 percent days of drug use
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=195 A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Response — 47.5; 29.6; 51.6; 63.3 percentage of participants
N/A N=40 Clinical Trial to Evaluate the Safety and Efficacy of Scarclinic™ Thin in Surgical Scars
Hypertrophic Surgical Scar
Primary: Change From Baseline in Vancouver Scar Scale Score(VSS) at 3 Months — -3.80; -2.61 units on a scale
Phase 2 N=39 Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
N/A N=25 Continuous Positive Airway Pressure (CPAP), Oral Appliance and Physical Exercise in the Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Objective Sleep Parameters
N/A N=14 Role of Endorphins in Perception of Dyspnea With Resistive Loading in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Intensity of Breathlessness — 77; 83 units on a scale — p=.0004
Phase 2 N=8 Precedex Versus Propofol-Awakening for Reducing Brain Injury Expansion
Brain Injury · Intracranial Pressure
Primary: Lactate/Pyruvate (L/P)Ratio — 103.1; 33.8 ratio
Phase 3 N=341 Efficacy of Esomeprazole in Patients With Frequent Heartburn
Heartburn
Primary: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment — 46.79; 30.93 Percentage of heartburn free days
Phase 1 N=19 Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicities (DLT) — 1; 2; 0 participants
Phase 3 N=280 Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
Hepatitis B
Primary: Percentage of Participants With HBV DNA < 400 Copies/mL at Week 96 — 89.4; 86.3 percentage of participants — p=0.43
Phase 2 N=217 A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
Primary: Participants Categorized by Best Response as Determined by Central Review — 7; 21; 40; 71 Participants
N/A N=102 Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain
Chronic Low Back Pain
Primary: Morphine Consumption in the First 48 Hours After Surgery — 309; 195 mg
Phase 2 N=204 Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
Prostatic Neoplasms
Primary: Percentage of Participants With Prostate Specific Antigen (PSA) Best Response — 51.7; 60.2; 28.1 Percentage of participants
Phase 2 N=31 Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
Prostatic Cancer
Primary: Efficacy of Quinacrine, Based on Prostate Specific Antigen (PSA) Response in Patients With Androgen-independent Metastatic Prostate Cancer — 1 Participants
Phase 1 N=30 Understanding Dexmedetomidine in Neonates After Open Heart Surgery
Tetrology of Fallot · Heart Ventricle · Hypoplastic Left Heart
Primary: PK Profile of Dexmedetomidine — 110 mL/min